Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Health Services Research in Oncology. Part I: End-of-Life Care
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Volumetric modulated arc therapy in patients with lung cancer, prostate cancer, high-risk gliomas and tumors in head and neck]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for non-contact thermal screening as an effective means of identifying cases of COVID-19
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in August 2020: administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pegvaliase in phenylketonuria]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Kaiku Health Service for symptom management of cancer patients
2020	Health Information and Quality Authority (HIQA)	Review of international public policy responses to easing restrictions introduced to limit the spread of COVID-19
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 1; Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 2 (Appendix)
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital dermatoscopy for dysplastic nevi]
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Indego Exoskeleton for walking rehabilitation
2020	Health Information and Quality Authority (HIQA)	Analysis of excess all-cause mortality in Ireland during the COVID-19 epidemic
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Somatostatin analogs with lutetium-177 in neuroendocrine tumors]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Lokomat robot for walking rehabilitation
2020	Agency for Healthcare Research and Quality (AHRQ)	Nonopioid pharmacologic treatments for chronic pain
2020	Health Information and Quality Authority (HIQA)	Scoping report: universal influenza vaccination in children
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on physical distancing in the context of COVID-19
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ustekinumab in Crohn’s disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for accuracy of salivary samples in SARS-CoV-2 detection compared with nasopharyngeal, oropharyngeal or lower respiratory tract samples
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ozone therapy]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information for health insurance fund members on prenatal testing]
2020	Agency for Healthcare Research and Quality (AHRQ)	Opioid treatments for chronic pain
2020	Health Information and Quality Authority (HIQA)	Scoping evidence summary for surgical outcomes in patients with COVID-19
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency ablation in benign bone tumors]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for SARS-CoV-2 viral load and infectivity over the course of an infection
2020	NIHR Health Technology Assessment programme	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2020	Agency for Care Effectiveness (ACE)	Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for aerosol generating procedures: risk of transmission of SARS-CoV-2 from patients without clinical symptoms
2020	Ontario Health	10-kHz high-frequency spinal cord stimulation for adults with chronic noncancer pain: a health technology assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endoscopic full-thickness resection of colorectal lesions]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (multiple sclerosis) - Addendum to Commission A20-59]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for care pathways support for the resumption of scheduled hospital care in the context of COVID-19
2020	Ontario Health	Continual Long-Term Physiotherapy After Stroke: A Health Technology Assessment
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Ontario Health	Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults: A Health Technology Assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intra-arterial chemotherapy for retinoblastoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020	Adelaide Health Technology Assessment (AHTA)	Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intranasal esketamine for severe resistant major depression]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V]
2020	Ontario Health	5-Aminolevulinic Acid Hydrochloride (5 ALA)–Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with yellow fever vaccination
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intrathecal baclofen pump in spastic patients]
2020	Ontario Health	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with oral cholera vaccination
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endometrial microbiome test in assisted reproduction]
2020	Ontario Health	Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Migalastat for Fabry disease]
2020	Agency for Healthcare Research and Quality (AHRQ)	Prevention, diagnosis, and management of opioids, opioid misuse, and opioid use disorder in older adults
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: safety of switching biologics and their interchangeability]
2020	Health Technology Wales (HTW)	The clinical effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis
2020	Agency for Care Effectiveness (ACE)	Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020	National Institute for Health and Care Excellence (NICE)	Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 617
2020	Agency for Care Effectiveness (ACE)	Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020	Agency for Healthcare Research and Quality (AHRQ)	Resource allocation and pandemic response: an evidence synthesis to inform decision making
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 618
2020	NIHR Health Technology Assessment programme	Basic versus biofeedback-mediated intensive pelvic floor muscle training for women with urinary incontinence: the OPAL RCT
2020	Agency for Care Effectiveness (ACE)	Epoprostenol for treating pulmonary arterial hypertension
2020	Agency for Healthcare Research and Quality (AHRQ)	Retention strategies for medications for addiction treatment in adults with opioid use disorder
2020	National Institute for Health and Care Excellence (NICE)	Sotagliflozin with insulin for treating type 1 diabetes. NICE technology appraisal guidance 622
2020	NIHR Health Technology Assessment programme	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study
2020	Agency for Care Effectiveness (ACE)	Vonoprazan for treating helicobacter pylori infection
2020	National Institute for Health and Care Excellence (NICE)	Patiromer for treating hyperkalaemia. NICE technology appraisal guidance 623
2020	Agency for Care Effectiveness (ACE)	Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020	National Institute for Health and Care Excellence (NICE)	Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2020	National Institute for Health and Care Excellence (NICE)	Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal). NICE technology appraisal guidance 625
2020	Agency for Care Effectiveness (ACE)	Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020	National Institute for Health and Care Excellence (NICE)	Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 626
2020	Agency for Care Effectiveness (ACE)	Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020	National Institute for Health and Care Excellence (NICE)	Lenalidomide with rituximab for previously treated follicular lymphoma. NICE technology appraisal guidance 627
2020	NIHR Health Technology Assessment programme	Dementia Care Mapping to reduce agitation in care home residents with dementia: the EPIC cluster RCT
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Healthcare Research and Quality (AHRQ)	Strategies for patient, family, and caregiver engagement
2020	National Institute for Health and Care Excellence (NICE)	Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 628
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: update of the systematic review of the effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus infections in children]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism
2020	Agency for Care Effectiveness (ACE)	Adalimumab for treating inflammatory conditions
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Paediatric cardiac surgery - literature review
2020	National Institute for Health and Care Excellence (NICE)	Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. NICE technology appraisal guidance 629
2020	NIHR Health Technology Assessment programme	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis
2020	Agency for Care Effectiveness (ACE)	Abiraterone for treating metastatic prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Larotrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 630
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
2020	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632